According to @StockMKTNewz, Nvidia (NVDA) and Eli Lilly (LLY) announced an investment of up to $1 billion to create a new AI co-innovation lab focused on applying AI to tackle enduring challenges in the pharmaceutical industry. Source: @StockMKTNewz on X, Jan 12, 2026. The source highlights a maximum capital commitment and an AI-driven focus for pharma problem-solving, but provides no details on timeline, governance, expected ROI, or revenue contribution. Source: @StockMKTNewz on X, Jan 12, 2026. For trading relevance, the headline confirms a material capex and partnership catalyst for NVDA and LLY in AI and biopharma; the source does not cite any cryptocurrency market implications. Source: @StockMKTNewz on X, Jan 12, 2026.